论文部分内容阅读
目的:探讨舒利迭与孟鲁司特联用对咳嗽变异性哮喘(CVA)患者的价值。方法:96例CVA患者采用随机数字表随机分为观察组和对照组,每组48例,其中观察组采用舒利迭联合孟鲁司特治疗,而对照组仅用舒利迭治疗,疗程均为8周。评价比较2组临床疗效,观察2组治疗前后临床症状、肺功能等指标及不良反应。随访6个月分别观察其复发率。结果:治疗8周后观察组总有效率为95.8%(46/48)高于对照组的83.3%(40/48)(P<0.05);治疗后观察组咳嗽缓解及消失时间均短于对照组(P<0.05);治疗8周后2组肺功能均改善(P<0.05),观察组改善更明显(P<0.05)。治疗期间观察组不良反应率为12.5%(6/48)高于对照组的6.3%(3/48)(P>0.05)。随访6个月后疾病复发率观察组为4.3%(2/46)低于对照组的22.5%(9/40)(P<0.05)。结论:对于CVA患者,舒利迭联合孟鲁司特治疗CVA有效,可以改善患者临床症状和肺功能,且不良反应少,复发率低。
Objective: To investigate the value of seretide in combination with montelukast for patients with cough variant asthma (CVA). Methods: Ninety-six patients with CVA were randomly divided into observation group and control group with 48 cases in each group. The observation group was treated with seretide combined with montelukast and the control group with only seretide, For 8 weeks. Evaluation of the clinical efficacy of two groups were compared, before and after treatment to observe the clinical symptoms, lung function and other indicators and adverse reactions. The follow-up of 6 months were observed the recurrence rate. Results: After 8 weeks of treatment, the total effective rate in observation group was 95.8% (46/48), which was significantly higher than that in control group (83.3%, 40/48) (P <0.05). After treatment, the relief and disappearance of cough in observation group were shorter than those in control group (P <0.05). After 8 weeks of treatment, the lung function of both groups improved (P <0.05), and the improvement of the observation group was more obvious (P <0.05). The rate of adverse reactions in the observation group during treatment was 12.5% (6/48) higher than that in the control group (3/48) (P> 0.05). The disease recurrence rate in the observation group after 6 months of follow-up was 4.3% (2/46) in the observation group, which was lower than that in the control group (22.5%, 9/40) (P <0.05). CONCLUSION: In patients with CVA, seretide and montelukast are effective in treating CVA, which can improve clinical symptoms and pulmonary function in patients with less adverse reactions and lower recurrence rate.